4641-38-7

Usage

Uses

Used in Pharmaceutical Industry:
2,6-dichloro-4-hydroxybenzoic acid is used as an intermediate in the synthesis of pharmaceuticals for its potential anti-inflammatory and antioxidant properties. It is being investigated for its role in the development of new drugs for various medical conditions, including its potential as an anti-inflammatory agent.
Used in Agrochemical Industry:
In the agrochemical industry, 2,6-dichloro-4-hydroxybenzoic acid is used as a herbicide due to its ability to inhibit certain enzymes in plants. This property makes it a valuable compound in the development of herbicidal products to control unwanted plant growth.
Used in Medical Device Manufacturing:
2,6-dichloro-4-hydroxybenzoic acid is utilized in the production of antimicrobial coatings for medical devices and equipment. Its antimicrobial properties help prevent the growth of bacteria and other microorganisms on the surfaces of medical devices, reducing the risk of infections.
Used in Coatings and Surface Treatments:
The antimicrobial properties of 2,6-dichloro-4-hydroxybenzoic acid also make it suitable for use in coatings and surface treatments in various industries. It can be incorporated into paints, coatings, and other surface treatments to provide antimicrobial protection and improve hygiene in various settings, such as hospitals, food processing facilities, and public spaces.

Upstream product

• 94278-69-0 2,6-dichloro-4-methoxybenzoic acid 
• 88135-16-4 2,6-dichloro-4-nitrobenzoyl chloride 
• 22509-50-8 2,6-dichloro-4-nitrobenzoic acid 
• 232275-49-9 methyl 4-amino-2,6-dichlorobenzoate 
• 232275-50-2 methyl 2,6-dichloro-4-nitrobenzoate 

Relevant academic research and scientific papers

PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS

The use is described of CCR5 antagonists of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R 1 is hydrogen or alkyl; R 2 is substituted phenyl, substituted heteroary

Inhibitors of α4 mediated cell adhesion

The present invention relates to a pharmaceutical composition comprising as an active ingredient a compound of formula (I), wherein Ring A is an aromatic or a heterocyclic ring; Q is a bond, carbonyl, lower alkylene, lower alkenylene, —O-(lower alkylene)-, etc.; n is 0, 1 or 2; Z is oxygen or sulfur, W is oxygen, sulfur, —CH═CH—, —NH— or —N═CH—; R1, R2and R3are the same or different and are hydrogen, halogen, hydroxyl, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, etc.; R4is tetrazolyl, carboxyl group, amide or ester; R5is hydrogen, nitro, amino, hydroxyl, lower alkanoyl, lower alkyl etc.; R6is selected from (a) a substituted or unsubstituted phenyl group, (b) a substituted or unsubstituted pyridyl group, (c) a substituted or unsubstituted thienyl group, (d) a substituted or unsubstituted benzofuranyl group, etc.; or a pharmaceutically acceptable salt thereof.

Piperazine derivatives useful as CCR5 antagonists

The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1is hydrogen or alkyl; R2is substituted phenyl, substituted heter

Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: Discovery of TR-14035, a dual α4β7/α4β1 integrin antagonist

α4β1 and α4β7 integrins are key regulators of physiologic and pathologic responses in inflammation and autoimmune disease. The effectiveness of anti-integrin antibodies to attenuate a number of inflammatory/immune conditions provides a strong rationale to target integrins for drug development. Important advances have been made in identifying potent and selective candidates, peptides and peptidomimetics, for further development. Herein, we report the discovery of a series of novel N-benzoyl-L-biphenylalanine derivatives that are potent inhibitors of α4 integrins. The potency of the initial lead compound (1: IC50 α4β7/α4β1 =5/33 μM) was optimized via sequential manipulation of substituents to generate low nM, orally bioavailable dual α4β1/α4β7 antagonists. The SAR also led to the identification of several subnanomolar antagonists (134, 142, and 143). Compound 81 (TR-14035; IC50 α4β7/α4β1 =7/87 nM) has completed Phase I studies in Europe. The synthesis, SAR and biological evaluation of these compounds are described.

2-SACCHARINYLMETHYL ARYL CARBOXYLATES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND COMPOSITIONS AND METHOD OF USE THEREOF

A compound having the formula: STR1 wherein Ar, R 4 and R 5 are defined herein have pharmaceutical utility as proteolytic enzyme inhibitors.

PROTEOLYTIC ENZYME INHIBITION METHOD

4-R 4-R 5-2-Saccharinylmethyl aryl carboxylates, useful in the treatment of degenerative diseases, are prepared by reacting a 4-R. sup.4-R 5-2-halomethylsaccharin with an arylcarboxylic acid in the presence of an acid-acceptor.